```
 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:25:57 ON 28 JAN 2008

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.63       0.63

FILE 'CAPLUS' ENTERED AT 16:27:56 ON 28 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Jan 2008  VOL 148 ISS 5
FILE LAST UPDATED: 27 Jan 2008  (20080127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s alginate
L1        25929 ALGINATE

=> s thermo reversible
          41716 THERMO
         156039 REVERSIBLE
L2          406 THERMO REVERSIBLE
                (THERMO(W)REVERSIBLE)

=> s L1 and L2
L3            6 L1 AND L2
```

=> d ibib ab l-6

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:990351 CAPLUS
DOCUMENT NUMBER: 147:350337
TITLE: Semi-IPN hydrogel based on scleroglucan and alginate: drug delivery behavior and mechanical characterisation
AUTHOR(S): Matricardi, P.; Onorati, I.; Masci, G.; Coviello, T.; Alhaique, F.
CORPORATE SOURCE: Department of Chemistry and Technology of Biologically Active Compounds, "Sapienza" University of Rome, Rome, 00185, Italy
SOURCE: Journal of Drug Delivery Science and Technology (2007), 17(3), 193-197
CODEN: JDDSAL; ISSN: 1773-2247
PUBLISHER: Editions de Sante
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This paper deals with the characterization of the semi-IPN based on a scleroglucan/borax hydrogel with interspersed alginate chains, with regard to both its physicochem. properties and its suitability for modified drug release formulations. In particular, the feasibility of a drug delivery system based on this new polysaccharidic matrix was explored in terms of ability of the network to discriminate the releases of model drugs with different steric hindrance. The investigated mech. properties of the semi-IPN hydrogel evidenced the relevant effect of alginate on the scleroglucan/borax system: expts. in shear oscillation regime showed that the rheol. properties of the polymeric system are more than additive; in fact it has been observed that alginate induces an increase in the hydrogel storage modulus of an order of magnitude. Optical data collected in circular dichroic expts. showed no interactions, at mol. level, between scleroglucan and alginate in solution, irresp. of the presence of borax. The studied semi-IPN is thermo irreversible in the temperature range that was explored.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:233048 CAPLUS
DOCUMENT NUMBER: 146:428604
TITLE: pA process of preparing modified release dosage forms of roxithromycin
INVENTOR(S): Sampad, Bhattacharya; Vyas, Tushar; Mayank, Joshi
PATENT ASSIGNEE(S): Alembic Ltd., India
SOURCE: Indian Pat. Appl., 20pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2003MU00276	A	20050204	IN 2003-MU276	20030313
PRIORITY APPLN. INFO.:			IN 2003-MU276	20030313

AB The present invention describes a process of preparing a pharmaceutical composition of roxithromycin, which provides the release of the active agent in a modified manner over a desire period for the treatment of various types of infections. The process provides a matrix tablet, comprising of roxithromycin with thermo-reversible, rate controlling, nonionic block

copolymers which may also enhance the drug solubility and hence imparts improved bioavailability. More particularly, the invention relates to a unique process of preparing the pharmaceutical compns. of roxithromycin for oral administration.

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:14806 CAPLUS
DOCUMENT NUMBER: 120:14806
TITLE: Diffusion and concentration profiles of drugs in gels
AUTHOR(S): Upadrashta, Sathyanarayana M.; Haeglund, Bert O.; Sundeloef, Lars Olof
CORPORATE SOURCE: Sch. Pharm., Univ. Missouri, Kansas City, MO, 64110, USA
SOURCE: Journal of Pharmaceutical Sciences (1993), 82(11), 1094-8
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A versatile membrane-less method was used to study the diffusion of acetoaminophen, ibuprofen, indomethacin, theophylline, and chlorpheniramine in thermo-reversible gels. Two independent ways to calculate the diffusion coeffs. and to verify Fickian transport are presented; the most sensitive criterion for Frickian transport being an agreement between the concentration profile for the drug in the gel and the free diffusion
model. The diffusion of acetaminophen, ibuprofen, and indomethacin was studied at different temps. in 1% (weight/weight) agarose gels. The diffusion coeffs. for these drugs were essentially the same as in water, and the apparent diffusion activation energies are close to that for self diffusion of water (4.62 kcal/mol), indicating a common mechanism for the diffusion of these drugs in the gel. The diffusivity of chlorpheniramine maleate was also studied in 4% (weight/weight) agarose gels or with part of the agarose substituted with other polymers (e.g., chitosan and sodium alginate). These two oppositely charged polymers, mixed together, were found to occupy an "equivalent polymer volume" that was 3-fold larger than the same amount of each of the constituents. When chitosan and gelatin-B were mixed into the agarose gel, non-Fickian transport resulted. Such non-Fickian transport was also observed with theophylline diffusing in a mixture of agarose, chitosan, and sodium alginate at a low pH.

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:136271 CAPLUS
DOCUMENT NUMBER: 116:136271
TITLE: Ophthalmic drug delivery with thermo-irreversible gels of polyoxyalkylenes and ionic polysaccharide
INVENTOR(S): Viegas, Tacey X.; Reeve, Lorraine E.; Henry, Raymond L.
PATENT ASSIGNEE(S): Mediventures, Inc., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5077033	A	19911231	US 1990-563638	19900807
US 5277911	A	19940111	US 1990-604705	19901026
US 5376693	A	19941227	US 1990-604701	19901026
CA 2040460	A1	19911102	CA 1991-2040460	19910415
CA 2040460	C	19970610		

CA 2044878	A1	19920208	CA 1991-2044878		19910618
CA 2044878	C	20001226			
EP 470703	A1	19920212	EP 1991-306120		19910705
EP 470703	B1	19960911			
R: CH, DE, DK, FR, GB, IT, LI, SE					
JP 04230636	A	19920819	JP 1991-165877		19910705
JP 3320748	B2	20020903			
EP 719545	A1	19960703	EP 1996-200145		19910705
EP 719545	B1	20020605			
R: CH, DE, DK, FR, GB, IT, LI, SE					

PRIORITY APPLN. INFO.:

US 1990-517273	A	19900501
US 1990-517277	A	19900501
US 1990-517278	A	19900501
US 1990-587282	A	19900501
US 1990-563638	A2	19900807
US 1990-563639	A	19900807
US 1990-563640	A	19900807
US 1990-563764	A	19900807
US 1990-604701	A	19901026
US 1990-604705	A	19901026
EP 1991-306120	A3	19910705

AB An ophthalmic preparation which is a liquid at room temperature and a thermo-reversible gel at body temperature comprises an anionic polysaccharide, a polyoxyalkylene block copolymer, a biol. active agent, and optionally a latent form of a counter-ion capable of thermo-irreversibly gelling the composition An antibacterial formulation contained mafenide acetate 11.2, Na alginate 0.5, Poloxamer 407 19.0, and Tris-HCl buffer 69.3 %. The formulation was clear, straw colored, exhibited gelation at .apprx.33°, and when the solution was exposed to an equal amount of a 2 % CaCl2 solution, it formed a thermo-irreversible gel.

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:91418 CAPLUS
DOCUMENT NUMBER: 116:91418
TITLE: Topical drug delivery with thermo-irreversible gels
INVENTOR(S): Viegas, Tacey X.; Reeve, Lorraine E.; Henry, Raymond L.
PATENT ASSIGNEE(S): Mediventures, Inc., USA
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5071644	A	19911210	US 1990-563639	19900807
CA 2044878	A1	19920208	CA 1991-2044878	19910618
CA 2044878	C	20001226		
EP 470703	A1	19920212	EP 1991-306120	19910705
EP 470703	B1	19960911		
R: CH, DE, DK, FR, GB, IT, LI, SE				
JP 04230636	A	19920819	JP 1991-165877	19910705
JP 3320748	B2	20020903		
EP 719545	A1	19960703	EP 1996-200145	19910705
EP 719545	B1	20020605		
R: CH, DE, DK, FR, GB, IT, LI, SE				

PRIORITY APPLN. INFO.:

US 1990-563638	A	19900807
US 1990-563639	A	19900807
US 1990-563640	A	19900807
US 1990-563764	A	19900807

	US 1990-604701	A	19901026
	US 1990-604705	A	19901026
	EP 1991-306120	A3	19910705

AB An aqueous topical drug composition comprises a ionic polysaccharide, a polyoxyalkylene block copolymer, a buffer, and, optionally, a latent form of a counterion, capable of thermo-irreversibly gelling the ionic polysaccharide. The composition is liquid at room temperature or below, and is a thermo-reversible gel at body temperature A composition was made of mafenide acetate 11.2, Na alginate 0.5, Poloxamer 407 (polyoxyethylene-polyoxypropylene block copolymer) 19.0, and 0.1M Tris-HCl buffer 69.3% by weight The counter ion may be microencapsulated or incorporated into a ion-exchange resin.

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1985:165385 CAPLUS
DOCUMENT NUMBER:	102:165385
ORIGINAL REFERENCE NO.:	102:25991a,25994a
TITLE:	Solubility of protein fibers obtained from casein solutions and liquid two-phase water-casein-sodium alginate systems
AUTHOR(S):	Antonov, Yu. A.; Zhuravskaya, N. A.; Tolstoguzov, V. B.
CORPORATE SOURCE:	A. N. Nesmeyanov Inst. Organo-Elem. Compd., Moscow, 117 813, USSR
SOURCE:	Nahrung (1985), 29(1), 39-47 CODEN: NAHRAR; ISSN: 0027-769X
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The solubility of protein and protein-polysaccharide matrix fibers obtained from casein solns. and 2-phase water-casein-Na alginate [9005-38-3] (W-C-A) systems in water and in 1M NaCl solns. at different pH at 20 and 100° was studied. The matrix fibers obtained from the 2-phase W-C-A system were considerably less soluble than those from the casein solns. This difference was seen particularly clearly when the pH was 5-7. However, it disappeared with the spinning 2-phase system at >80°. An assumption has been made about the matrix fibers being either mixed gels of the thermo-reversible, soluble Ca caseinate and thermo-irreversible insol. Ca alginate, or complex protein-polysaccharide gels formed with the participation of Ca2+. This latter assumption is in conformity with the negligible solubility of the protein fibers obtained as a result of the lyotropic gelation of the skimmed milk proteins.

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.26	25.89
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.80	-4.80

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:29:57 ON 28 JAN 2008

Connecting via Winsock to STN

```
Welcome to STN International!  Enter x:x

LOGINID:SSPTAESC1618

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 16:41:35 ON 28 JAN 2008
FILE 'CAPLUS' ENTERED AT 16:41:35 ON 28 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    25.26      25.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -4.80      -4.80

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    25.26      25.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -4.80      -4.80

FILE 'CAPLUS' ENTERED AT 16:41:42 ON 28 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Jan 2008  VOL 148 ISS 5
FILE LAST UPDATED: 27 Jan 2008  (20080127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 16:25:57 ON 28 JAN 2008)

     FILE 'CAPLUS' ENTERED AT 16:27:56 ON 28 JAN 2008
L1         25929 S ALGINATE
L2           406 S THERMO REVERSIBLE
L3             6 S L1 AND L2

     FILE 'CAPLUS' ENTERED AT 16:41:42 ON 28 JAN 2008
```

```
=> s kappa carrageenan
        88707 KAPPA
        14964 CARRAGEENAN
L4       2765 KAPPA CARRAGEENAN
                (KAPPA(W)CARRAGEENAN)

=> s l1 and l4
L5        443 L1 AND L4

=> s gel
L6     528502 GEL

=> s l5 and l6
L7        163 L5 AND L6

=> s drug delivery
       771189 DRUG
       286680 DELIVERY
L8     203025 DRUG DELIVERY
                (DRUG(W)DELIVERY)

=> s l8 and l7
L9         17 L8 AND L7

=> d ibib ab 1-17

L9   ANSWER 1 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2006:649152  CAPLUS
DOCUMENT NUMBER:         145:102581
TITLE:                   Method for thickening or gelation of polysaccharides
                         and edible gels manufactured by this method
INVENTOR(S):             Shiga, Keitaro
PATENT ASSIGNEE(S):      Unitec Foods Co., Ltd., Japan
SOURCE:                  Jpn. Kokai Tokkyo Koho, 14 pp.
                         CODEN: JKXXAF
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     JP 2006174789        A     20060706    JP 2004-373364         20041224
PRIORITY APPLN. INFO.:                      JP 2004-373364         20041224
AB   Polysaccharides dissolved or dispersed in media are electrified for
     thickening or gelation.  Thus, aqueous solution of LM pectin was electrified
(at
     14 V 10 A for 5 min using Pt-coated Ti electrodes) to give a gel with Bx
     5, pH 4.0, and similar texture as conventional pectin gel.

L9   ANSWER 2 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2006:54363  CAPLUS
DOCUMENT NUMBER:         144:135276
TITLE:                   Oral compositions containing 5-HT3 receptor
                         antagonists
INVENTOR(S):             Jin, Chikara; Tatsumi, Noboru; Dairaku, Masatake;
                         Fukushima, Fuminori; Shimizu, Toshio; Togashi, Mitsuo;
                         Ninomiya, Hiroshi
PATENT ASSIGNEE(S):      Ohta Pharmaceutical Co., Ltd., Japan
SOURCE:                  PCT Int. Appl., 28 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
```

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006006595	A1	20060119	WO 2005-JP12835	20050712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2006028028	A	20060202	JP 2004-205043	20040712
US 2007128285	A1	20070607	US 2006-566829	20060131
PRIORITY APPLN. INFO.:			JP 2004-205043 A	20040712
			WO 2005-JP12835 W	20050712

AB It is intended to provide a medicinal composition for oral use which contains a 5-HT3 receptor antagonist, is excellent in storage stability, suffers from little syneresis, has a high uniformity and a good appearance, can be easily taken due to smoothness to swallow and is suitable for self medication. More specifically speaking, it is intended to provide a jelly-type medicinal composition for oral use containing a 5-HT3 receptor antagonist, a gelling agent and water and having a pH value of 3 to 7. The gelling agent is selected from the group consisting of carrageenan, low-methoxy pectin, agar, alginic acid, sodium alginate, gelatin, mannan, konjac, konjac mannan, glucomannan, chitosan, xanthan gum, tamarind seed polysaccharides, gellan gum, and karaya gum. The medicinal composition may further contain a thickener. For example, an oral gel composition (pH 6.5) contained granisetron hydrochloride 0.1474, κ-carrageenan 0.4, ι-carrageenan 0.9, locust bean gum 0.4, dextrin 5, citric acid 0.12, Na citrate 1, Na polyacrylate 0.004, D-sorbitol 56, glycerin 27, Na pyrosulfite 0.1, propylparaben 0.5 g, and flavor q.s.
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:902127 CAPLUS
DOCUMENT NUMBER: 141:370567
TITLE: Homogeneous, thermoreversible alginate films and soft capsules made therefrom
INVENTOR(S): Modliszewski, James J.; Ballard, Arthur D.; Sewall, Christopher J.; Blakemore, William R.; Riley, Peter J.
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091538	A2	20041028	WO 2004-US11907	20040414
WO 2004091538	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2522298	A1	20041028	CA 2004-2522298		20040414
US 20050086777	A1	20050113	US 2004-824793		20040414
US 2005014852	A1	20050120	US 2004-824688		20040414
US 2005013847	A1	20050120	US 2004-824957		20040414
US 2005019374	A1	20050127	US 2004-824860		20040414
US 2005019294	A1	20050127	US 2004-824919		20040414
US 2005019295	A1	20050127	US 2004-824956		20040414
US 2005048185	A1	20050303	US 2004-824977		20040414
US 2005084516	A1	20050421	US 2004-824689		20040414
EP 1622594	A2	20060208	EP 2004-759583		20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004009334	A	20060425	BR 2004-9334		20040414
CN 1791417	A	20060621	CN 2004-80013896		20040414
CN 1791388	A	20060621	CN 2004-80013902		20040414
CN 1791382	A	20060621	CN 2004-80013903		20040414
CN 1791389	A	20060621	CN 2004-80013907		20040414
CN 1791385	A	20060621	CN 2004-80014006		20040414
CN 1794979	A	20060628	CN 2004-80014023		20040414
JP 2006524743	T	20061102	JP 2006-513097		20040414
IN 2005DN04641	A	20070928	IN 2005-DN4641		20051013
PRIORITY APPLN. INFO.:			US 2003-462617P	P	20030414
			US 2003-462721P	P	20030414
			US 2003-462758P	P	20030414
			US 2003-462783P	P	20030414
			US 2003-462785P	P	20030414
			US 2003-462792P	P	20030414
			US 2003-462793P	P	20030414
			US 2003-462794P	P	20030414
			WO 2004-US11907	W	20040414

AB The present invention is directed to a homogeneous, thermoreversible gel film comprising a film forming amount of a water soluble, thermoreversible alginate, and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent; and processes for the preparation thereof. The present invention is also directed to soft capsules and solid forms containing the gel film, as well as processes for the preparation thereof. A formulation was prepared containing water 840.3, propylene glycol alginate 91.2, hydroxyethyl cellulose 1.9, kappa carrageenan 24.0, potassium citrate 2.9, starch 207.8, sorbitol 264.4, and glycerin 88.2 g. The formulation showed sufficient dry film strength for use in soft capsule manufacture

L9 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:902126 CAPLUS
DOCUMENT NUMBER:	141:370566
TITLE:	Process for making gel films as drug delivery systems
INVENTOR(S):	Ballard, Arthur D.; Sewall, Christopher J.; Modliszewski, James J.; Blakemore, William R.; Riley, Peter J.
PATENT ASSIGNEE(S):	FMC Corporation, USA

SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091537	A2	20041028	WO 2004-US11906	20040414
WO 2004091537	A3	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2522297	A1	20041028	CA 2004-2522297	20040414
US 2005008677	A1	20050113	US 2004-824793	20040414
US 2005014852	A1	20050120	US 2004-824688	20040414
US 2005013847	A1	20050120	US 2004-824957	20040414
US 2005019374	A1	20050127	US 2004-824860	20040414
US 2005019294	A1	20050127	US 2004-824919	20040414
US 2005019295	A1	20050127	US 2004-824956	20040414
US 2005048185	A1	20050303	US 2004-824977	20040414
US 2005084516	A1	20050421	US 2004-824689	20040414
EP 1617815	A2	20060125	EP 2004-759582	20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009329	A	20060425	BR 2004-9329	20040414
CN 1791417	A	20060621	CN 2004-80013896	20040414
CN 1791388	A	20060621	CN 2004-80013902	20040414
CN 1791382	A	20060621	CN 2004-80013903	20040414
CN 1791389	A	20060621	CN 2004-80013907	20040414
CN 1791385	A	20060621	CN 2004-80014006	20040414
CN 1794979	A	20060628	CN 2004-80014023	20040414
JP 2007528357	T	20071011	JP 2006-513096	20040414
IN 2005DN04650	A	20071005	IN 2005-DN4650	20051013

PRIORITY APPLN. INFO.:

US 2003-462617P	P	20030414
US 2003-462721P	P	20030414
US 2003-462758P	P	20030414
US 2003-462783P	P	20030414
US 2003-462785P	P	20030414
US 2003-462792P	P	20030414
US 2003-462793P	P	20030414
US 2003-462794P	P	20030414
WO 2004-US11906	W	20040414

AB The present invention is directed to a process for making homogeneous, thermoreversible gel films comprising the steps of: (i) heating, hydrating, mixing, solubilizing, and, optionally, de-aerating a high solids, low moisture film forming composition in an apparatus providing sufficient shear, temperature and residence time to form a homogeneous molten composition, wherein the temperature is at or above the solubilizing temperature of said composition; (ii) feeding the molten composition into at least one of a mixer, pump or devolatilizer; and (iii) cooling the homogeneous molten composition at or below

its gelling temperature to form said gel films. The present invention is also directed to various products made from such films, such as the gel films themselves, soft capsules, solid dosage forms and delivery systems. Capsules were made from formulation containing water 836.3, carrageenan D 40.5, Guar ULV50 49.5, starch B760 220.8, sorbitol 264.4, glycerin 88.2 g according to above method.

L9 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:902123 CAPLUS
DOCUMENT NUMBER: 141:370565
TITLE: Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
INVENTOR(S): Modliszewski, James J.; Ballard, Arthur D.; Sewall, Christopher J.; Blakemore, William R.; Riley, Peter J.
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091533	A2	20041028	WO 2004-US11632	20040414
WO 2004091533	A3	20060518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005008677	A1	20050113	US 2004-824793	20040414
US 2005014852	A1	20050120	US 2004-824688	20040414
US 2005013847	A1	20050120	US 2004-824957	20040414
US 2005019374	A1	20050127	US 2004-824860	20040414
US 2005019294	A1	20050127	US 2004-824919	20040414
US 2005019295	A1	20050127	US 2004-824956	20040414
US 2005048185	A1	20050303	US 2004-824977	20040414
US 2005084516	A1	20050421	US 2004-824689	20040414
EP 1620059	A2	20060201	EP 2004-759560	20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009345	A	20060425	BR 2004-9345	20040414
CN 1791417	A	20060621	CN 2004-80013896	20040414
CN 1791388	A	20060621	CN 2004-80013902	20040414
CN 1791382	A	20060621	CN 2004-80013903	20040414
CN 1791389	A	20060621	CN 2004-80013907	20040414
CN 1791385	A	20060621	CN 2004-80014006	20040414
CN 1794979	A	20060628	CN 2004-80014023	20040414
CN 1871016	A	20061129	CN 2004-80015167	20040414
JP 2007526211	T	20070913	JP 2006-510070	20040414
IN 2005DN04646	A	20070928	IN 2005-DN4646	20051013
PRIORITY APPLN. INFO.:			US 2003-462617P P	20030414
			US 2003-462721P P	20030414
			US 2003-462758P P	20030414
			US 2003-462783P P	20030414

US 2003-462785P	P	20030414
US 2003-462792P	P	20030414
US 2003-462793P	P	20030414
US 2003-462794P	P	20030414
WO 2004-US11632	W	20040414

AB The present invention is directed to a delivery system comprising a homogeneous, thermoreversible gel film, wherein the gel film comprises: (i) a film forming amount of kappa-2 carrageenan and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent; and (ii) an active substance. The present invention is also directed to a process for the manufacture thereof. A film formulation was prepared containing water 55.6, propylene glycol alginate 1.2, potassium alginate 2.1, carrageenan C 2.7, M-100 15.0, sorbitol 18.0, and glycerin 6.0%.

L9 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:902122 CAPLUS
DOCUMENT NUMBER:	141:370564
TITLE:	Homogeneous, thermoreversible gels containing reduced viscosity carrageenan and products made therefrom
INVENTOR(S):	Sewall, Christopher J.; Riley, Peter J.; Blakemore, William R.
PATENT ASSIGNEE(S):	FMC Corporation, USA
SOURCE:	PCT Int. Appl., 43 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	9
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091532	A2	20041028	WO 2004-US11631	20040414
WO 2004091532	A3	20060518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2522296	A1	20041028	CA 2004-2522296	20040414
US 2005008677	A1	20050113	US 2004-824793	20040414
US 2005014852	A1	20050120	US 2004-824688	20040414
US 2005013847	A1	20050120	US 2004-824957	20040414
US 2005019374	A1	20050127	US 2004-824860	20040414
US 2005019294	A1	20050127	US 2004-824919	20040414
US 2005019295	A1	20050127	US 2004-824956	20040414
US 2005048185	A1	20050303	US 2004-824977	20040414
US 2005084516	A1	20050421	US 2004-824689	20040414
EP 1628620	A2	20060301	EP 2004-750153	20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009343	A	20060425	BR 2004-9343	20040414
CN 1791417	A	20060621	CN 2004-80013896	20040414
CN 1791388	A	20060621	CN 2004-80013902	20040414
CN 1791382	A	20060621	CN 2004-80013903	20040414
CN 1791389	A	20060621	CN 2004-80013907	20040414

CN 1791385	A	20060621	CN 2004-80014006		20040414
CN 1794979	A	20060628	CN 2004-80014023		20040414
CN 1832748	A	20060913	CN 2004-80013920		20040414
JP 2007526210	T	20070913	JP 2006-510069		20040414
IN 2005DN04639	A	20070928	IN 2005-DN4639		20051013
PRIORITY APPLN. INFO.:			US 2003-462617P	P	20030414
			US 2003-462721P	P	20030414
			US 2003-462758P	P	20030414
			US 2003-462783P	P	20030414
			US 2003-462785P	P	20030414
			US 2003-462792P	P	20030414
			US 2003-462793P	P	20030414
			US 2003-462794P	P	20030414
			WO 2004-US11631	W	20040414

AB The present invention is directed to a homogeneous, thermoreversible gel comprising carrageenan wherein the carrageenan has a viscosity of less than 10 cP at 75° when measured in a 0.10M aqueous sodium chloride solution containing 1.5% by weight of the carrageenan based on the weight of all components in the solution, and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent, wherein the gel has a solids content of at least 40%. The present invention is also directed to processes for the preparation thereof, as well as to variety of products containing the gel including edible products, soft capsules, hard capsules and solid forms encapsulating powders, tablets, caplets, etc. A film formulation contained water 825, starch B760 225, carrageenan Z 90, sorbitol 272.2, and glycerin 90.8 g.

L9 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:902119 CAPLUS
DOCUMENT NUMBER:	141:370562
TITLE:	Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
INVENTOR(S):	Ballard, Arthur D.; Sewall, Christopher J.; Modliszewski, James J.; Blakemore, William R.; Riley, Peter J.
PATENT ASSIGNEE(S):	FMC Corporation, USA
SOURCE:	PCT Int. Appl., 52 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	9
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091529	A2	20041028	WO 2004-US11601	20040414
WO 2004091529	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2522293	A1	20041028	CA 2004-2522293	20040414
US 2005008677	A1	20050113	US 2004-824793	20040414
US 2005014852	A1	20050120	US 2004-824688	20040414

US 2005013847	A1	20050120	US 2004-824957		20040414
US 2005019374	A1	20050127	US 2004-824860		20040414
US 2005019294	A1	20050127	US 2004-824919		20040414
US 2005019295	A1	20050127	US 2004-824956		20040414
US 2005048185	A1	20050303	US 2004-824977		20040414
US 2005084516	A1	20050421	US 2004-824689		20040414
EP 1617825	A2	20060125	EP 2004-759552		20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004009342	A	20060425	BR 2004-9342		20040414
CN 1791417	A	20060621	CN 2004-80013896		20040414
CN 1791388	A	20060621	CN 2004-80013902		20040414
CN 1791382	A	20060621	CN 2004-80013903		20040414
CN 1791389	A	20060621	CN 2004-80013907		20040414
CN 1791385	A	20060621	CN 2004-80014006		20040414
CN 1794979	A	20060628	CN 2004-80014023		20040414
JP 2006526057	T	20061116	JP 2006-510061		20040414
IN 2005DN04645	A	20070928	IN 2005-DN4645		20051013
PRIORITY APPLN. INFO.:			US 2003-462617P	P	20030414
			US 2003-462721P	P	20030414
			US 2003-462758P	P	20030414
			US 2003-462783P	P	20030414
			US 2003-462785P	P	20030414
			US 2003-462792P	P	20030414
			US 2003-462793P	P	20030414
			US 2003-462794P	P	20030414
			WO 2004-US11601	W	20040414

AB The present invention is directed to a homogeneous, thermoreversible gel film comprising a film forming amount of low viscosity polymannan gum, e.g., low viscosity guar gum, and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent; and processes for the preparation thereof. The present invention is also directed to soft capsules and solid forms containing the gel film, as well as processes for the preparation thereof. A formulation was prepared containing water 836.3, potassium alginate 60, carrageenan L 30, starch B760 220.8, sorbitol 264.4, and glycerin 88.2 g. The formulation showed sufficient dry film strength for use in soft capsule manufacture

L9 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:902118 CAPLUS
DOCUMENT NUMBER: 141:370561
TITLE: Delivery systems of homogeneous thermoreversible alginate films
INVENTOR(S): Ballard, Arthur D.; Sewall, Christopher J.; Modliszewski, James J.; Blakemore, William R.; Riley, Peter J.
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091528	A2	20041028	WO 2004-US11600	20040414
WO 2004091528	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 20050086777	A1	20050113	US 2004-824793		20040414
US 2005014852	A1	20050120	US 2004-824688		20040414
US 20050138477	A1	20050120	US 2004-824957		20040414
US 2005019374	A1	20050127	US 2004-824860		20040414
US 2005019294	A1	20050127	US 2004-824919		20040414
US 2005019295	A1	20050127	US 2004-824956		20040414
US 2005048185	A1	20050303	US 2004-824977		20040414
US 2005084516	A1	20050421	US 2004-824689		20040414
EP 1622588	A2	20060208	EP 2004-759551		20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004009336	A	20060425	BR 2004-9336		20040414
CN 1791417	A	20060621	CN 2004-80013896		20040414
CN 1791388	A	20060621	CN 2004-80013902		20040414
CN 1791382	A	20060621	CN 2004-80013903		20040414
CN 1791389	A	20060621	CN 2004-80013907		20040414
CN 1791385	A	20060621	CN 2004-80014006		20040414
CN 1794979	A	20060628	CN 2004-80014023		20040414
JP 2007525451	T	20070906	JP 2006-510060		20040414
IN 2005DN04643	A	20070928	IN 2005-DN4643		20051013
PRIORITY APPLN. INFO.:			US 2003-462617P	P	20030414
			US 2003-462721P	P	20030414
			US 2003-462758P	P	20030414
			US 2003-462783P	P	20030414
			US 2003-462785P	P	20030414
			US 2003-462792P	P	20030414
			US 2003-462793P	P	20030414
			US 2003-462794P	P	20030414
			WO 2004-US11600	W	20040414

AB The present invention is directed to a delivery system comprising a homogeneous, thermoreversible gel film, wherein the gel film comprises: (i) a film forming amount of water soluble thermoreversible alginate and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent; and (ii) an active substance. The present invention is also directed to a process for the manufacture thereof. A film formulation for preparation of capsule contained water

834.7, kappa-2 carrageenan 40.5, potassium alginate 31.5, propylene glycol alginate 18.0, M-100 227.3, sorbitol 272.2, and glycerin 90.8 g.

L9 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:902117 CAPLUS
DOCUMENT NUMBER:	141:370560
TITLE:	Delivery systems of homogeneous thermoreversible low-viscosity polymannan gum films
INVENTOR(S):	Ballard, Arthur D.; Sewall, Christopher; Modliszewski, James J.; Blakemore, William R.; Riley, Peter J.
PATENT ASSIGNEE(S):	FMC Corporation, USA
SOURCE:	PCT Int. Appl., 40 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	9
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091527	A2	20041028	WO 2004-US11561	20040414
WO 2004091527	A3	20050818		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005008677	A1	20050113	US 2004-824793	20040414
US 2005014852	A1	20050120	US 2004-824688	20040414
US 2005013847	A1	20050120	US 2004-824957	20040414
US 2005019374	A1	20050127	US 2004-824860	20040414
US 2005019294	A1	20050127	US 2004-824919	20040414
US 2005019295	A1	20050127	US 2004-824956	20040414
US 2005048185	A1	20050303	US 2004-824977	20040414
US 2005084516	A1	20050421	US 2004-824689	20040414
EP 1620114	A2	20060201	EP 2004-750147	20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1791417	A	20060621	CN 2004-80013896	20040414
CN 1791388	A	20060621	CN 2004-80013902	20040414
CN 1791382	A	20060621	CN 2004-80013903	20040414
CN 1791389	A	20060621	CN 2004-80013907	20040414
CN 1791385	A	20060621	CN 2004-80014006	20040414
CN 1794979	A	20060628	CN 2004-80014023	20040414
JP 2007526209	T	20070913	JP 2006-510049	20040414
IN 2005DN04644	A	20071109	IN 2005-DN4644	20051013
PRIORITY APPLN. INFO.:			US 2003-462617P P	20030414
			US 2003-462721P P	20030414
			US 2003-462758P P	20030414
			US 2003-462783P P	20030414
			US 2003-462785P P	20030414
			US 2003-462792P P	20030414
			US 2003-462793P P	20030414
			US 2003-462794P P	20030414
			WO 2004-US11561 W	20040414

AB The present invention is directed to a delivery system comprising a homogeneous, thermoreversible gel film comprising (i) a film forming amount of low-viscosity polymannan gum, e.g., low-viscosity guar gum, and optionally at least one of a plasticizer, a second film former, a bulking agent, and a pH controlling agent; and (ii) an active substance. The present invention is also directed to a process for the manufacture these films. For example, films were prepared by using blend compns. of low-viscosity guar gum ULV50 in combination with either kappa carrageenan or kappa carrageenan and/or iota carrageenan and their properties were studied. Use of kappa carrageenan in combination with guar increased the film strength compared to guar alone. Addition of KCl increased the gel temperature and also the 40% solids gel strength. Further, KCl addition and varying ratios of film forming ingredients control cast film strength and gel melt temperature When kappa carrageenans were used in combination with low-viscosity guar, control of cation divalency desirably prevents/minimizes gel hardening and brittleness.

L9 ANSWER 10 OF 17 CAPLUS

ACCESSION NUMBER: 2004:738570 CAPLUS
DOCUMENT NUMBER: 141:206064
TITLE: Production of films useful for food and other packagings
INVENTOR(S): Tsukioka, Tadao; Nishimura, Misao; Wakabayashi, Tomoaki; Mukoyama, Mayumi
PATENT ASSIGNEE(S): Tsukioka K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004248665	A	20040909	JP 2003-190646	20030702

PRIORITY APPLN. INFO.: JP 2002-378015 A 20021226
AB An edible film contains starch as the main component with Na alginate and calcium ion mixture (weight ratio of 100 : 0.1 to 0.5). The production procedure involves the following 4 steps: (1) preparation of a mixture of starch and carrageenan in water, (2) formation of a liquid membrane by heating the starch and carrageenan solution at ≥ 60° and casting on the base material, (3) cooling the membrane to ≤ 40°, making the carrageenan in the form of gel, and finally, (4) heat-drying of the wet membrane. The edible film is not only useful for wrapping food, but also useful for industrial goods like drugs.

L9 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:268340 CAPLUS
DOCUMENT NUMBER: 140:286585
TITLE: Granular dried jellies and their use as swallowing aids, foods for seniors, drug-containing jellies, dried desserts, and instant food materials
INVENTOR(S): Wakabayashi, Kenji; Miyamoto, Yasunori; Taniguchi, Shigeru
PATENT ASSIGNEE(S): Okura Pharmaceutical Co., Ltd., Japan; Meiji Milk Products, Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004097114	A	20040402	JP 2002-264502	20020910
JP 3835544	B2	20061018		

PRIORITY APPLN. INFO.: JP 2002-264502 20020910
AB Claimed are freeze-dried jelly granules and dried jellies cut into granules, which are reversibly return to gel form by mixing with water. Thus, 5 g freeze-dried jelly granules containing xanthan gum and RL-200-J (locust bean gum) was mixed with 4 mL water to quickly return to jelly.

L9 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:950463 CAPLUS
DOCUMENT NUMBER: 140:8815
TITLE: Hydrocolloid cellular solid matrices
INVENTOR(S): Nussinovitch, Amos
PATENT ASSIGNEE(S): Israel

SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. 6,589,328.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003224022	A1	20031204	US 2003-371205	20030224
IL 104441	A	20010128	IL 1993-104441	19930119
WO 9417137	A1	19940804	WO 1994-EP107	19940117
W: AU, CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6589328	B1	20030708	US 1997-877804	19970618

PRIORITY APPLN. INFO.: IL 1993-104441 A 19930119
WO 1994-EP107 W 19940117
US 1995-491983 B2 19950718
US 1997-877804 A2 19970618

AB The invention relates to novel hydrocolloid cellular solid matrixes having predetd. moisture absorption properties, caloric value, biodegradability, pore size, pore d., pore distribution and structure. Certain cellular solid matrixes of the invention can be used as edibles, and these can be produced as calorie-less, low calorie, high calorie and ultra-high calorie content cellular solids. Certain types of cellular solid matrixes can be used in medicine and also in a variety of industries. An air-filled gel was prepared by mixing calcium hydrogen orthophosphate 1, sodium alginate 2, calcium carbonate 1, glucono δ-lactone 1, and citric acid 2%.

L9 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:719331 CAPLUS
DOCUMENT NUMBER: 139:235459
TITLE: Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
INVENTOR(S): Yokoyama, Hideakira; Hirata, Akihiko; Hamamoto, Hidetoshi; Yamazaki, Keiko; Fujii, Takeru
PATENT ASSIGNEE(S): Medrx Co., Ltd., Japan
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074086	A1	20030912	WO 2003-JP2410	20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477964	A1	20030912	CA 2003-2477964	20030303
AU 2003211627	A1	20030916	AU 2003-211627	20030303
EP 1488812	A1	20041222	EP 2003-743551	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1638804	A	20050713	CN 2003-805259		20030303
JP 2004002320	A	20040108	JP 2003-57654		20030304
US 2005089577	A1	20050428	US 2004-506512		20041222
PRIORITY APPLN. INFO.:			JP 2002-57943	A	20020304
			WO 2003-JP2410	W	20030303

AB It is intended to provide a liquid matrix for medicinal use in which a drug can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being a liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness, and gels in vivo so as to control the release speed, and liquid oral prepns. using the same. Namely, disclosed is a liquid matrix which is a liquid auxiliary facilitating the swallowing of a drug, characterized by containing a water-soluble polymer gelling under acidic conditions and the break stress of the gel being about 3.0x103 N/m2 or more. Liquid oral prepns. having favorable slow release properties even though being a liquid is also disclosed. A liquid composition containing amoxicillin 0.75, clarithromycin 0.2, pectin 4, gellan gum 1, sucrose 20, and water q.s. to 200 g was formulated.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:563021 CAPLUS
DOCUMENT NUMBER: 139:106498
TITLE: Method of artificial insemination by timed release of sperm from capsules or solid beads
INVENTOR(S): Chou, Kuo-Chuan Karen; Wang, Henry Y.
PATENT ASSIGNEE(S): Board of Trustees Operating Michigan State University, USA; University of Michigan
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6596310	B1	20030722	US 2000-644483	20000823
PRIORITY APPLN. INFO.:			US 2000-644483	20000823

AB A method is provided for encapsulating sperm in a particle wherein the particle provides for the timed release of the sperm. In particular, the method uses a gel forming polymer to form the particle and a medium for maintaining most of the sperm in a non-capacitated stage while it is encapsulated. Further provided is a method for artificial insemination using the encapsulated sperm wherein the sperm is naturally or artificially capacitated after the artificial insemination. In an embodiment, capsules containing a core of sperm in a semen extender are formed as a mixture having membranes of different thicknesses to provide varying time of sperm release. In another embodiment, the sperm and extender are dispersed throughout solid beads that vary in chemical property and diameter to provide varying time of sperm release. The extender may be free of glucose, xanthine oxidase and H2O2, and contain fructose, fructose-6-phosphate, pyruvate, lactate or mixts. thereof as a carbohydrate source.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:637505 CAPLUS

DOCUMENT NUMBER: 137:159374
TITLE: Gel preparations for internal use
INVENTOR(S): Nakamura, Tohru
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064120	A1	20020822	WO 2002-JP1181	20020213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002232164	A1	20020828	AU 2002-232164	20020213
EP 1366761	A1	20031203	EP 2002-712309	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004072724	A1	20040415	US 2003-467321	20030806
PRIORITY APPLN. INFO.:			JP 2001-35074	A 20010213
			WO 2002-JP1181	W 20020213

AB Disclosed are gel prepns. for internal use characterized by comprising a first edible gel containing a drug ingredient and being decomposed in the digestive tract and a second edible gel containing a drug ingredient and showing a different behavior in the digestive tract from the first edible gel. Thus, it is possible to provide gel prepns. for internal use appropriate for drugs and quasi drugs which can be easily taken and in which the release points and release speeds of the drug ingredients can be controlled. A fast-release gel containing acetaminophen, gellan gum, calcium lactate, sucrose, and water, and a sustained-release gel containing acetaminophen, sodium alginate, and water were prepared and combined together.
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:890578 CAPLUS
DOCUMENT NUMBER: 137:114360
TITLE: Drug-squeezing effect in tablets with κ -carrageenan and methyl glycol chitosan as drug carriers
AUTHOR(S): Kanbayashi, Shintarou
CORPORATE SOURCE: Dep. Environ. Chem., Tokyo Inst., Polytechnic Univ., Ogawanisi-machi, Kodaira-shi, Tokyo, 187-0035, Japan
SOURCE: Kobunshi Ronbunshu (2001), 58(11), 617-623
CODEN: KBRBA3; ISSN: 0386-2186
PUBLISHER: Kobunshi Gakkai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB Tablets were prepared with polyion complex (PIC) formers as drug carriers. In these materials either κ -carrageenan (Car) or sodium alginate (Alg) was the polyanion and Me glycol chitosan (MG) was the polycation. The release of the theophylline contained in the tablets was

assessed via absorption photometry (271 nm). The tablets composed of Car and MG (CarMG) and of Alg and MG (AlgMG) were first placed in artificial gastric juice (pH 1.2), then transferred into artificial intestinal juice (pH 6.8) after a specified amount of time. A "squeezing effect" was observed, wherein the rate of release rose sharply when the tablets were transferred from the artificial gastric juice into the artificial intestinal juice. Two squeezing effect models could be proposed for the tablets being transferred from gastric juice to intestinal juice: (1) With CarMG, a disintegration model, wherein tablet disintegration accompanies gel dissoln. within the swelling layer formed on the tablet surface: and (2) With AlgMG, a contraction model, wherein PIC formation is accompanied by volume contraction of the swelling layer.

L9 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:46434 CAPLUS
DOCUMENT NUMBER: 130:114815
TITLE: Use of natural polysaccharides in the microencapsulation techniques
AUTHOR(S): Murano, Erminio
CORPORATE SOURCE: POLY-tech Research Center Scrl, Trieste, I-34012, Italy
SOURCE: Journal of Applied Ichthyology (1998), 14(3-4), 245-249
CODEN: JAICEF; ISSN: 0175-8659
PUBLISHER: Blackwell Wissenschafts-Verlag GmbH
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A brief review with 75 refs. is given on natural polysaccharides used in microencapsulation techniques. Alginate, carrageenan, agarose, chitosan, and gellan gum, an extracellular anionic polysaccharide secrete from microorganisms, are used or proposed. Monomeric composition, degree of substitution, kinetics of gel formation, gel strength, and shrinkage of matrixes greatly affect both cell viability and rate of release of drugs, vaccines, and other mols. entrapped in the gel matrix.
REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h
COST IN U.S. DOLLARS SINCE FILE ENTRY 62.95 TOTAL SESSION 88.84

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY -13.60 TOTAL SESSION -18.40

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:45:09 ON 28 JAN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAESC1618

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 16:48:21 ON 28 JAN 2008

```
FILE 'CAPLUS' ENTERED AT 16:48:21 ON 28 JAN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    62.95      88.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -13.60     -18.40

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    62.95      88.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -13.60     -18.40

FILE 'CAPLUS' ENTERED AT 16:48:31 ON 28 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Jan 2008  VOL 148 ISS 5
FILE LAST UPDATED: 27 Jan 2008  (20080127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 16:25:57 ON 28 JAN 2008)

     FILE 'CAPLUS' ENTERED AT 16:27:56 ON 28 JAN 2008
L1         25929 S ALGINATE
L2           406 S THERMO REVERSIBLE
L3             6 S L1 AND L2

     FILE 'CAPLUS' ENTERED AT 16:41:42 ON 28 JAN 2008
L4          2765 S KAPPA CARRAGEENAN
L5           443 S L1 AND L4
L6        528502 S GEL
L7           163 S L5 AND L6
L8        203025 S DRUG DELIVERY
L9            17 S L8 AND L7

     FILE 'CAPLUS' ENTERED AT 16:48:31 ON 28 JAN 2008
```

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	89.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-18.40

STN INTERNATIONAL LOGOFF AT 16:48:46 ON 28 JAN 2008